MPLN vs. NEO, DFIN, NVEE, FLYW, TASK, CTOS, EVH, PSFE, OLO, and RDWR
Should you be buying MultiPlan stock or one of its competitors? The main competitors of MultiPlan include NeoGenomics (NEO), Donnelley Financial Solutions (DFIN), NV5 Global (NVEE), Flywire (FLYW), TaskUs (TASK), Custom Truck One Source (CTOS), Evolent Health (EVH), Paysafe (PSFE), OLO (OLO), and Radware (RDWR). These companies are all part of the "business services" industry.
MultiPlan vs.
NeoGenomics (NASDAQ:NEO) and MultiPlan (NYSE:MPLN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings.
98.5% of NeoGenomics shares are owned by institutional investors. Comparatively, 87.2% of MultiPlan shares are owned by institutional investors. 1.3% of NeoGenomics shares are owned by insiders. Comparatively, 8.0% of MultiPlan shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
NeoGenomics has a net margin of -11.92% compared to MultiPlan's net margin of -163.30%. NeoGenomics' return on equity of -2.10% beat MultiPlan's return on equity.
NeoGenomics has higher earnings, but lower revenue than MultiPlan. NeoGenomics is trading at a lower price-to-earnings ratio than MultiPlan, indicating that it is currently the more affordable of the two stocks.
NeoGenomics has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, MultiPlan has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500.
In the previous week, NeoGenomics had 6 more articles in the media than MultiPlan. MarketBeat recorded 6 mentions for NeoGenomics and 0 mentions for MultiPlan. NeoGenomics' average media sentiment score of 0.94 beat MultiPlan's score of 0.00 indicating that NeoGenomics is being referred to more favorably in the media.
NeoGenomics presently has a consensus price target of $19.60, indicating a potential upside of 114.21%. MultiPlan has a consensus price target of $26.25, indicating a potential upside of 19.54%. Given NeoGenomics' stronger consensus rating and higher probable upside, analysts plainly believe NeoGenomics is more favorable than MultiPlan.
NeoGenomics received 497 more outperform votes than MultiPlan when rated by MarketBeat users. Likewise, 70.81% of users gave NeoGenomics an outperform vote while only 35.71% of users gave MultiPlan an outperform vote.
Summary
NeoGenomics beats MultiPlan on 15 of the 18 factors compared between the two stocks.
Get MultiPlan News Delivered to You Automatically
Sign up to receive the latest news and ratings for MPLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MultiPlan Competitors List
Related Companies and Tools
This page (NYSE:MPLN) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy MPLN Stock Free MPLN Stock Alerts